Secondary preventive ACE inhibitors/angiotensin receptor blockers (ARBs) and P2Y12-inhibitors were more frequently used in patients with type 1 diabetes compared to propensity score-matched patients without diabetes (Table 2). The gene discussed is P2RY12; the disease is diabetes mellitus.